Hyperfine (HYPR) Return on Capital Employed (2021 - 2026)
Hyperfine (HYPR) posted Return on Capital Employed of 72.91% for Q1 2026, up 27.93% on a QoQ basis from 101.17% in Q4 2025, and up 1736.0% year-over-year from 3.97% in Q1 2025.
Hyperfine (HYPR) Return on Capital Employed (2021 - 2026) Analysis & Trends
Hyperfine's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 72.91% for Q1 2026.
- Quarterly Return on Capital Employed rose 1736.0% year-over-year to 72.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 72.91% (up 1736.0% YoY) and the FY2025 annual result came in at 81.78%, down 1804.0% from the prior year.
- Return on Capital Employed was 72.91% for Q1 2026 at Hyperfine, up from 101.17% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 45.1% in Q1 2022 and bottomed at 121.01% in Q3 2025.
- A 5-year average of 69.13% and a median of 60.56% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 5108 bps — and 2026, when it soared 1736 bps.
- Hyperfine's Return on Capital Employed stood at 55.8% in 2022, then rose by 4 bps to 53.54% in 2023, then sank by 46 bps to 78.0% in 2024, then fell by 30 bps to 101.17% in 2025, then climbed by 28 bps to 72.91% in 2026.
- Business Quant data shows HYPR's Return on Capital Employed at 72.91% in Q1 2026, 101.17% in Q4 2025, and 121.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | -72.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.91% |
| Dec 31, 2025 | -101.17% |
| Sep 30, 2025 | -121.01% |
| Jun 30, 2025 | -102.20% |
| Mar 31, 2025 | -90.27% |
| Dec 31, 2024 | -78.00% |
| Sep 30, 2024 | -69.94% |
| Jun 30, 2024 | -62.13% |
| Mar 31, 2024 | -56.42% |
| Dec 31, 2023 | -53.54% |
| Sep 30, 2023 | -50.30% |
| Jun 30, 2023 | -47.24% |
| Mar 31, 2023 | -52.58% |
| Dec 31, 2022 | -55.80% |
| Sep 30, 2022 | -60.56% |
| Jun 30, 2022 | -55.97% |
| Mar 31, 2022 | -45.10% |
| Dec 31, 2021 | -34.24% |